Related StoriesFDA grants accelerated approval for Tagrisso to take care of sufferers with advanced NSCLCNew results reveal association between colorectal cancer and melanoma medication treatmentMD Anderson study reveals why chemotherapy medicines not effective for most pancreatic cancer patientsHe continuing, As a global leader in precision medicine, The Kids's Hospital of Philadelphia has made significant investment in its Center for Applied Genomics with the goal of diagnosing and curing pediatric disorders. We have already made strides harnessing this technology to better understand and treat cancers, autism, asthma, diabetes and several other childhood illnesses.Drugs or surgery are used to reduce testosterone production or to block testosterone’s results. However, sometimes prostate cancer can continue to grow even when testosterone amounts are low. Men with these cancers are thought to possess castration-resistant prostate cancer. Zytiga is a pill that targets a proteins called cytochrome P450 17A1 which plays a significant role in the production of testosterone. The drug functions by decreasing the production of this hormone that would stimulate tumor cells to continue growing. The application form was reviewed beneath the FDA’s concern review program, which gives for an expedited six-month review for medicines that may offer main advancements in treatment, or provide a treatment when no adequate therapy exists. Zytiga has been approved ahead of the product’s June 20, 2011 regulatory goal date.